Recipharm appoints General Manager for its new Blow Fill Seal subsidiary in Kaysersberg, France

Recipharm, the leading contract development and manufacturing organisation, is pleased to announce that it has appointed Yves Buelens to the position of General Manager for its wholly owned new subsidiary Kaysersberg Pharmaceuticals SAS.

Yves Buelens has a Master in Pharmaceutical Sciences from the University of Brussels, Belgium and a specialisation as Industrial Pharmacist (QP). He brings a broad experience to the Group acquired in various roles in the pharmaceutical industry as well as in contract manufacturing organisations in Europe. Yves has been the plant manager for the Kaysersberg facility since 2014.

Commenting on the appointment, CEO Thomas Eldered said “Yves Buelens brings valuable experience to Recipharm having worked with a variety of pharmaceutical companies including CDMO’s. I am sure he and his team will contribute greatly to the ongoing development of Recipharm and in particular with this exciting new technology”.

Yves Buelens said “I'm looking forward to become a member of the Recipharm family.I believe it will be a fruitful environment for growth and expansion of the Kaysersberg site. The long-term contract with Alcon will be an excellent foundation and milestone for other business opportunities and the proven quality track record will be the cornerstone to attract new customers. The Recipharm entrepreneurship combined with high technical skills of the Alsace workforce will give us a bright future together”.

For further information please visit www.recipharm.com or contact:
Thomas Eldered, CEO, thomas.eldered@recipharm.com, +46 8 602 52 10

Yves Buelens, General Manager, yves.buelens@recipharm.com, +33 3 8978 7601

For media enquiries, please contact Tristan Jervis or Alex Heeley at De Facto Communications: t.jervis@defacto.com or a.heeley@defacto.com , +44 207 861 3019/3043

About Recipharm
Recipharm is a leading CDMO (Contract Development and Manufacturing Organisation) in the pharmaceutical industry employing some 2,200 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material including API and pharmaceutical product development. Recipharm manufactures more than 400 different products to customers ranging from Big Pharma to smaller research- and development companies. Recipharm’s turnover is approximately SEK 3.4 billion and the Company operates development and manufacturing facilities in Sweden, France, the UK, Germany, Spain, Italy and Portugal and is headquartered in Jordbro, Sweden. The Recipharm B-share (RECI B) is listed on NASDAQ Stockholm.

For more information on Recipharm and our services, please visit www.recipharm.com

About Kaysersberg Pharmaceuticals SAS

Kaysersberg Pharmaceuticals employs around 260 people.  The company, including its main asset a manufacturing facility in Alsace, France, was acquired by Recipharm December 31, 2015. The facility was previously acquired by Alcon in 1984. Alcon is the second largest division of Novartis. The facility is dedicated to Blow Fill Seal (BFS)/Form Fill Seal technology, is well invested and fully GMP compliant with approvals from FDA, EU, ANVISA and Japan. It is 25.000 m2 with a manufacturing area of 7.000 m2 with 7 production lines and 10 packaging lines. The facility manufactures single dose units and has an advanced aseptic process for sterile liquid packaging applications in plastic containers. 

Recipharm AB (publ)
Corporate identity number 556498-8425
Address Lagervägen 7, SE-136 50 Jordbro, Sweden,  Telephone 46 8 602 52 00,  Fax  46 8 81 87 03

www.recipharm.com

Tags:

About Us

About RecipharmRecipharm is a leading CDMO (Contract Development and Manufacturing Organisation) in the pharmaceutical industry employing some 5 000 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, and pharmaceutical product development. Recipharm manufactures several hundred different products to customers ranging from Big Pharma to smaller research- and development companies. Recipharm’s turnover is approximately SEK 5.3 billion and the company operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US and is headquartered in Stockholm, Sweden. The Recipharm B-share (RECI B) is listed on Nasdaq Stockholm. For more information on Recipharm and our services, please visit www.recipharm.com

Subscribe

Documents & Links

Quotes

“Yves Buelens brings valuable experience to Recipharm having worked with a variety of pharmaceutical companies including CDMO’s. I am sure he and his team will contribute greatly to the ongoing development of Recipharm and in particular with this exciting new technology”
Thomas Eldered
“I'm looking forward to become a member of the Recipharm family.I believe it will be a fruitful environment for growth and expansion of the Kaysersberg site. The long-term contract with Alcon will be an excellent foundation and milestone for other business opportunities and the proven quality track record will be the cornerstone to attract new customers. The Recipharm entrepreneurship combined with high technical skills of the Alsace workforce will give us a bright future together”
Yves Buelens